{"url_path":"/sec/espr/8-k/2026-06-01/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-01","source_url":"https://www.sec.gov/Archives/edgar/data/1434868/0001628280-26-039518-index.html","accession_number":"0001628280-26-039518","cik":"0001434868","ticker":"ESPR","issuer_name":"Esperion Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1434868/0001628280-26-039518-index.html","primary_entity_key":"0001434868","primary_entity_name":"Esperion Therapeutics, Inc."},"word_count":83,"has_tables":true,"body_markdown":"Item 9.01. Financial Statements and Exhibits.\n\n(d) Exhibits.\n\nExhibit No.Description\n\n[10.1](exhibit10111.htm)\n\n[Esperion Therapeutics, Inc. 2022 Stock Option and Incentive Plan and its Amendments.](exhibit10111.htm)\n\n104Cover Page Interactive Data File (embedded within the Inline XBRL Document).\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nDate: June 1, 2026Esperion Therapeutics, Inc.\n\nBy:/s/ Sheldon L. Koenig\n\nSheldon L. Koenig\n\nPresident and Chief Executive Officer"}